Clinical trials
Prostatic Neoplasms, Castration-Resistant trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 7 |
| 2019 | 9 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Recruiting | 24 |
| Terminated | 11 |
| Active, not recruiting | 8 |
| Unknown status | 5 |
| Withdrawn | 5 |
| Not yet recruiting | 3 |
| No longer available | 1 |
| Temporarily not available | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 8 |
| Bayer | 7 |
| Novartis Pharmaceuticals | 6 |
| MacroGenics | 4 |
| Michael Graham PhD, MD | 3 |
| Nuvation Bio Inc. | 3 |
| Bristol-Myers Squibb | 2 |
| Cancer Research UK | 2 |
| Hoffmann-La Roche | 2 |
| Merck Sharp & Dohme LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms, Castration-Resistant | 85 |
| Prostatic Neoplasms | 33 |
| Neoplasms | 10 |
| Neoplasm Metastasis | 7 |
| Neoplasms by Site | 5 |
| Prostatic Diseases | 5 |
| Genital Diseases, Male | 4 |
| Genital Neoplasms, Male | 4 |
| Melanoma | 4 |
| Pancreatic Neoplasms | 4 |
Trials
Showing 1 to 25 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.